Long Term Efficacy and Safety of Dupilumab for Eosinophilic Esophagitis

Evidence-Based GI: An ACG Publication and Podcast - A podcast by American College of Gastroenterology - Wednesdays

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Swathi Eluri, MD, MS discuss “Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial,” by Summarizing Rothenber M, Dellon E, Collins M, et al. Lancet Gastroenterol Hep. 2023; 9: 990-1004